Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK
The DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.
Abstract
AIMS: To analyse the incidence and baseline clinical characteristics of patients with neovascular age-related macular degeneration (nAMD) treated with intravitreal anti-vascular endothelial growth factor (VEGF) injections in a defined UK region. METHODS: A standardised dataset was collected prospectively using an electronic medical record (EMR) system from 1 January 2008 to 21 June 2012 for all patients living in Gloucestershire who received intravitreal anti-VEGF injections for nAMD. RESULTS: Over the study period, 1207 eyes from 1033 patients began intravitreal anti-VEGF injections for nAMD. The annual incidence in the years after National Institute for Health and Care Excellence (NICE) technology appraisal 155 implementation was stable at 120 (95% CI 110 to 138) eyes or 100 (89 to 115) people per 100 000 population. The most common indication was occult choroidal neovascularisation (51%). Median baseline visual acuity (VA) was significantly higher for second treated than first treated eyes (66 and 56 letters, respectively; p<0.0001). Median baseline VA of fellow eyes increased from 47 (2008) to 67 letters (2012; p<0.005). The proportion of patients with baseline VA in the better eye ≥70 letters increased from 27.6% (2008) to 51.4% (2012; p<0.0001), while the proportion eligible at baseline for full or partial certificate of visual impairment decreased from 13.8% (2008) to 7.1% (2012; p<0.05). CONCLUSIONS: The incidence of patients undergoing anti-VEGF therapy for nAMD increased substantially following NICE approval of ranibizumab (August 2008), and has been stable since 2009. This equates to an annual UK incidence of 26 850 (21 320 to 32 440) eyes, similar to NICE estimates. Patients eligible for blindness certification before treatment decreased by half from 2008-2012. Prospective data collection using an EMR system is invaluable for efficient monitoring of real-world clinical care.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The overall effectiveness of anti-VEGF therapies in n-AMD is unquestionable.”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [4]
In the citing paper
“The introduction of anti-vascular endothelial growth factor (anti-VEGF) has made significant impact on the reduction of the visual loss due to neovascular age-related macular degeneration (n-AMD).”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [4]
Citations
Cites
Causes and Prevalence of Visual Impairment Among Adults in the UnitedStates
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.477 · Cited by 2,616
The Prevalence of Age-related Maculopathy in the Rotterdam Study
Vingerling, J. R., Dielemans, I., Hofman, A., Grobbee, D. E., Hijmering, M., Kramer, C. F. L., & de Jong, P. T. V. M. (1995) · Ophthalmology · doi:10.1016/s0161-6420(95)31034-2 · Cited by 815
Muñoz, B. (2000) · Archives of Ophthalmology · doi:10.1001/archopht.118.6.819 · Cited by 521
Incidence of Legal Blindness From Age-Related Macular Degeneration in Denmark: Year 2000 to 2010
Bloch, S. B., Larsen, M., & Munch, I. C. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.10.016 · Cited by 377
Rein, D. B. (2009) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2009.58 · Cited by 344
The estimated prevalence and incidence of late stage age related macular degeneration in the UK
Owen, C. G., Jarrar, Z., Wormald, R., Cook, D. G., Fletcher, A. E., & Rudnicka, A. R. (2012) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2011-301109 · Cited by 319
Age-Specific Causes of Bilateral Visual Impairment
Weih, L. M. (2000) · Archives of Ophthalmology · doi:10.1001/archopht.118.2.264 · Cited by 191
Vision-Related Function after Ranibizumab Treatment by Better- or Worse-Seeing Eye
Bressler, N. M., Chang, T. S., Suñer, I. J., Fine, J. T., Dolan, C., Ward, J., & Ianchulev, T. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2009.09.002 · Cited by 150
Causes of blind certifications in England and Wales: April 1999–March 2000
Bunce, C., & Wormald, R. (2007) · Eye · doi:10.1038/sj.eye.6702767 · Cited by 147
Time Trends in the Incidence and Causes of Blindness in Israel
Skaat, A., Chetrit, A., Belkin, M., Kinori, M., & Kalter-Leibovici, O. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.08.035 · Cited by 115
Research works printed but not linked: 4
- The Royal College of Ophthalmologists. AMD Service Provisions Sub- Committee, 2007, Commissioning contemporary AMD services: a guide for commissioners and clinicians (Version 3)
- Royal College of Ophthalmologists. AMD Provisions Sub-Committee, 2009, The
- National Institute for Health and Clinical Excellence, 2008, Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
- Fletcher, 2001, Low vision services for people with age-related macular degeneration in the UK: a review of service need and provision. Macular Disease Society
Cited by
Defining response to anti-VEGF therapies in neovascular AMD
Amoaku, W. M., Chakravarthy, U., Gale, R., Gavin, M., Ghanchi, F., Gibson, J., Harding, S., Johnston, R. L., Kelly, S., Lotery, A., et al. (2015) · Eye · doi:10.1038/eye.2015.48 · Cited by 355
Self-citationMehta, H., Tufail, A., Daien, V., Lee, A. Y., Nguyen, V., Ozturk, M., Barthelmes, D., & Gillies, M. C. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.12.002 · Cited by 265
Self-citationFinger, R. P., Daïen, V., Eldem, B. M., Talks, J. S., Korobelnik, J., Mitchell, P. L. R., Sakamoto, T., Wong, T. Y., Pantiri, K., & Carrasco, J. (2020) · BMC Ophthalmology · doi:10.1186/s12886-020-01554-2 · Cited by 163
van Asten, F., Michels, C. T. J., Hoyng, C. B., van der Wilt, G. J., Klevering, B. J., Rovers, M. M., & Grutters, J. P. C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197670 · Cited by 131
LEAN SIX SIGMA TECHNIQUES TO IMPROVE OPHTHALMOLOGY CLINIC EFFICIENCY
Ciulla, T. A., Tatikonda, M. V., ElMaraghi, Y. A., Hussain, R. M., Hill, A. L., Clary, J. M., & Hattab, E. M. (2017) · Retina · doi:10.1097/iae.0000000000001761 · Cited by 79
Metadata
- Authors
- Keenan, T. D. L., Kelly, S. P., Sallam, A., Mohamed, Q., Tufail, A., & Johnston, R. L.
- Affiliations
- Bolton NHS Foundation Trust (GB)
- Gloucestershire Hospitals NHS Foundation Trust (GB)
- Moorfields Eye Hospital NHS Foundation Trust (GB)
- Cheltenham General Hospital (GB)
- Corresponding author
- Johnston, Robert L
- Venue
- British Journal of Ophthalmology
- Publisher
- BMJ
- Published
- 2013-06-28
- Volume
- 97
- Issue
- 9
- Pages
- 1168-1172
- ISSN
- 0007-1161 (ISSN-L)
- 1468-2079
- OpenAlex
- W2152152687
- Cited by
- 29
- References
- 19
- Citations by year
- 2026: 1 · 2021: 1 · 2020: 2 · 2019: 3 · 2018: 3 · 2017: 4 · 2016: 4 · 2015: 5 · 2014: 5 · 2013: 1
- FWCI
- 4.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- British Journal of Ophthalmology (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- neovascular age-related macular degeneration, incidence, anti-VEGF therapy, intravitreal injection, ranibizumab, NICE technology appraisal, baseline visual acuity, Gloucestershire, treatment trends
- MeSH terms
- Aged, Aged, 80 and over, Female, United Kingdom, Humans, Macular Degeneration, Male, Middle Aged, Prospective Studies, Visual Acuity, Incidence, Age Distribution, Choroidal Neovascularization, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK. https://app.cochat.ai/papers/10.1136/bjophthalmol-2013-303233
- The paper
- Keenan, T. D. L., Kelly, S. P., Sallam, A., Mohamed, Q., Tufail, A., & Johnston, R. L. (2013). Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK. British Journal of Ophthalmology. https://doi.org/10.1136/bjophthalmol-2013-303233
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.